SCHEMBL4769726

SCHEMBL4769726

CS(=O)(=O)N(Cc1ccccc1Cl)c1ccc(C(C(N)=O)c2ccc(OCCO)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.44
GAA P10253 2/20 0.43
ALDH1A1 P00352 2/20 0.42
MAPT P10636 3/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
THRB P10828 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
NR1H4 Q96RI1 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TP53 P04637 1/20 0.37
MMP2 P08253 1/20 0.36
MMP9 P14780 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
F10 P00742 1/20 0.36
PPARG P37231 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4777345 0.81 GAA (0.55) POLBGAAALDH1A1MAPTMEN1
SCHEMBL4769719 0.80 POLB (0.43) POLBGAAALDH1A1MAPTMEN1
SCHEMBL4778588 0.79 GAA (0.65) POLBGAAALDH1A1MAPTMEN1
SCHEMBL4831822 0.79 GAA (0.47) GAAALDH1A1MAPTTP53
SCHEMBL4777639 0.79 GAA (0.44) POLBGAAALDH1A1MAPTMEN1
SCHEMBL4771116 0.78 GAA (0.43) POLBGAAALDH1A1MAPTMEN1
SCHEMBL4775063 0.78 GAA (0.40) POLBGAAALDH1A1MAPTMEN1
SCHEMBL4771381 0.77 GAA (0.41) POLBGAAALDH1A1MAPTMEN1
SCHEMBL4776388 0.77 ALDH1A1 (0.45) GAAALDH1A1MAPTMMP2MMP9
SCHEMBL4777536 0.75 GAA (0.58) POLBGAAALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 POLB 292/4885GAA 466/4885ALDH1A1 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.